Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05937295 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

Study acronym: FusionVAC22
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 9, 2024 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site contact updatedv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2023 to Sep 26, 2023
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in combination with anti-programmed cell death-ligand 1 immune checkpoint inhibition (ICI) by Atezolizumab (TecentriqTM) in patients with Fibrolamellar hepatocellular carcinoma (FL-HCC) or other cancer entities carrying the DNAJB1-PRKACA fusion transcript.
Trial Details
NCT Number NCT05937295
Lead Sponsor University Hospital Tuebingen
Conditions
(from sponsor)		 Fibrolamellar Hepatocellular Carcinoma
Related terms Fibrolamellar hepatocellular carcinoma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov